cyclophosphamide

Type: Keyphrase
Name: cyclophosphamide
First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

[News] Lenalidomide in combination with R-CHOP in lymphoma

Lenalidomide combined with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) shows activity in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), new research suggests. DLBCL has two major subtypes: germinal ... [Published Lancet Oncology - Oct 01 2014]
First reported Sep 28 2014 - Updated Sep 29 2014 - 3 reports

Order Cyclophosphamide Online With Free Dr Consultation, Cash On Delivery Of Cyclop

order cyclophosphamide online with free dr consultation, cash on delivery of cyclophosphamide no prescriptionMed Portal has proved its reliability and safety, working at pharmaceutical market since 2003. One of the most urgent problems in online pharmacy ... [Published Student Village - Sep 29 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 1 reports

Case Report: Primary renal lymphoma—a case report

OI: 10.3332/ecancer.2014.466N Geetha, Abdul Shahid, Varun Rajan and Priya Mary JacobPrimary renal lymphoma is a rare entity representing less than 1% of lesions in the kidney. We present the case of a 42-year-old male who was evaluated for pain and a ... [Published Ecancer Medicalscience - Sep 25 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Idelalisib (Zydelig) Approved in Europe

A much anticipated product, the first-in-class oral drug idelalisib ( Zydelig , Gilead Sciences, Inc), has now been granted marketing authorization by the European Commission for use in the treatment of chronic lymphocytic leukemia (CLL) and follicular ... [Published American Journal of Public Health - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 2 reports

Heat Biologics Commences Patient Dosing In Phase 2 Study Of Viagenpumatucel-L For The Treatment Of Non-Small Cell Lung Cancer

Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company") (Nasdaq: HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that it has initiated dosing in its Phase 2 trial of Viagenpumatucel-L ... [Published Benzinga.com - Sep 18 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Stanford in the Vale woman died after reaction to prescribed drug

A WOMAN who lived near Faringdon died from a “once in a million” complication due to prescribed medication, an inquest heard yesterday.Christine Beck, 67, was found collapsed in a ward at Oxford’s John Radcliffe Hospital on Sunday, March 30.Oxfordshire ... [Published Oxford Times - Sep 18 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 2 reports

Improved risk identification will aid fertility preservation in young male cancer patients

MEMPHIS, Tenn.By clarifying which patients are at highest risk for reduced sperm production as adults, researchers expect the findings to eventually increase use of pre-treatment fertility preservation methods such as sperm banking.The study involved ... [Published Bio-Medicine - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Non-Hodgkin Lymphoma Treatment Regimens: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® for Non-Hodgkin's Lymphomas. V4.2014. Available at: http://www.nccn.org. Accessed Sept 10, 2014.2. Goede V, Fischer K, Humphrey K, et al. Obinutuzumab ... [Published Chemotherapy Advisor - Sep 17 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Patent Application Titled "Method of Activation of Oxazaphosphorines" Published Online

By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a patent application by the inventors Spasojevic, Ivan ( Durham, NC ); Colvin, Michael O. ( Chapel Hill, NC ... [Published 4 Traders - Sep 10 2014]
First reported Sep 05 2014 - Updated Sep 06 2014 - 1 reports

Breast cancer specialist reports advance in treatment of triple-negative breast cancer

William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, served as study chair and lead author for a recently-published ... [Published Bio-Medicine - Sep 05 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Treatment of diffuse large-cell lymphoma with anti-CD20 antibody

The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy ... [Published Free Patents Online - Sep 02 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Advances in Hematopoietic Cell Transplant for Pediatric AML Reduce Toxicity and Expand Access, but Relapse Remains a Problem

Figures:John Perentesis, MDJohn Horan, MDOne of the real successes in using hematopoietic cell transplantation for children with AML has been in developing better conditioning regimens and the reduction in regimen-related toxicity.—John Horan, MDAdvances ... [Published The ASCO Post - Sep 02 2014]

Quotes

"The promising results from the DPX-Survivac Phase I/Ib ovarian cancer studies, as well as expanding scientific literature highlighting the clinical activity of immune modulators in lymphoma, provide a strong scientific rationale for this study. There is a clear and important unmet medical need in this area of lymphoma management and we are eager to evaluate the potential of this combination therapy to deliver clinical benefit to those patients" said Neil Berinstein, M D , Professor, Department of Medicine at the University of Toronto and medical oncologist at the Odette-Sunnybrook Cancer Centre...
...of anthracycline-based chemotherapy," said Jonathan Drachman, M D , Chief Medical Officer and Executive vice president, R&D at Seattle Genetics. "Maturing data from this Phase I trial in patients who have advanced or high-risk disease characteristics demonstrate durable progression-free survival and overall survival rates, supporting our belief that this novel ADCETRIS-containing regimen has the potential to redefine the treatment of frontline PTCL. This hypothesis is being tested in our ongoing Phase III clinical trial, called ECHELON-2."
"During microbial infection, macrophages are activated to produce cytokines to mediate immune response. Depending on the invading microbe and its biological properties, the host immune system utilizes different sets of cytokines to combat the invading pathogen locally and systemically."

More Content

All (118) | News (104) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
Prevention of Immune Nephritis by the Small Mol... [Published Plosone.org - 18 hours ago]
Immunovaccine Announces Plans for Phase II Clin... [Published Scottrade - Oct 01 2014]
[News] Lenalidomide in combination with R-CHOP ... [Published Lancet Oncology - Oct 01 2014]
Seattle Genetics announces encouraging data fro... [Published Individual.com - Sep 29 2014]
Cytoxan ach, Cytoxan doctor, overnight shipping... [Published Student Village - Sep 29 2014]
Cytotoxic Agents in Sarcoidosis: Which One to C... [Published General Medicine eJournal - Sep 29 2014]
Order Cyclophosphamide Online With Free Dr Cons... [Published Student Village - Sep 29 2014]
Forum Post: Cyclophosphamide and clinical trials [Published Macmillan Cancer Support - Sep 28 2014]
Generic Cyclophosphamide NO PRESCRIPTION Requir... [Published Student Village - Sep 28 2014]
ESMO Guideline for Mantle Cell Lymphoma [Published General Medicine eJournal - Sep 25 2014]
Case Report: Primary renal lymphoma—a case report [Published Ecancer Medicalscience - Sep 25 2014]
"Novel Compounds and Uses Thereof for Treating ... [Published HispanicBusiness.com - Sep 25 2014]
Anti-CD19 CAR T cells show promise in chemother... [Published Orthopedics Today - Sep 24 2014]
Mabion Signed An Agreement For The Realization ... [Published BioSpace - Sep 23 2014]
Markers for determination of patient responsive... [Published PharmCast - Sep 21 2014]
Idelalisib (Zydelig) Approved in Europe [Published American Journal of Public Health - Sep 19 2014]
Immunotherapy in Pediatric Malignancies [Published General Medicine eJournal - Sep 19 2014]
Bruton's TKIs and Treatment of B-Cell Malignancies [Published General Medicine eJournal - Sep 19 2014]
Does TapImmune Have With It Takes To Succeed? [Published Seeking Alpha - Sep 18 2014]
Entering the Era of Targeted Therapy for Chroni... [Published Journal of Clinical Oncology - Sep 18 2014]
Heat Biologics Commences Patient Dosing In Phas... [Published Benzinga.com - Sep 18 2014]
Heat Biologics Commences Patient Dosing in Phas... [Published Scottrade - Sep 18 2014]
Stanford in the Vale woman died after reaction ... [Published Oxford Times - Sep 18 2014]
Researchers Submit Patent Application, "Cyclosp... [Published 4 Traders - Sep 17 2014]
Non-Hodgkin Lymphoma Treatment Regimens: Chroni... [Published Chemotherapy Advisor - Sep 17 2014]
Improved risk identification will aid fertility... [Published Bio-Medicine - Sep 17 2014]
Improved risk identification will aid fertility... [Published Town Hall - Sep 16 2014]
An Overview of Chemotherapy-Related Cognitive D... [Published Cancernetwork.com - Sep 16 2014]
Ongoing Clinical Trials Actively Recruiting Pat... [Published The ASCO Post - Sep 15 2014]
Breast Cancer Has Led Me to Careers in Activism... [Published The ASCO Post - Sep 15 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Biotech Stock Kite Phama Explodes Higher After ... [Published Clusterstock - Aug 25 2014]
Shares of Kite Pharma are exploding higher in after-hours trading. The $827 million biotech firm just revealed positive outcomes from patients with aggressive non-Hodgkin's lymphoma after receiving its anti-CD19 treatment. KITE is up 35%. "The ...
Stem Cell Transplantation [Published Multiple Sclerosis Research - Aug 17 2014]
Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, Hagglund H, Krasulova E, Simões BP, Carlson K, Pohlreich D, Labopin M, Saccardi R, Comi G, Mancardi GL, Bacigalupo A, Ciceri F, Farge D. Autologous hematopoietic stem cell transplantation ...
Research and Markets: Cyclophosphamide (CAS 605... [Published Business Wire Manufacturing News - Aug 07 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/63jzc7/cyclophosphamide) has announced the addition of the "Cyclophosphamide (CAS 6055-19-2, 50-18-0) Market Research Report 2014" report to their offering. Cyclophosphamide ...
Autologous hematopoietic stem cell transplantat... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Jul 30 2014]
Background: Neuromyelitis optica (NMO) is an inflammatory autoimmune disorder of the central nervous system, hallmarked by pathogenic anti-aquaporin 4 antibodies. NMO prognosis is worse compared with multiple sclerosis. Objective: The European Group for ...
Rebound post-natallizumab: it is not as bad as ... [Published Multiple Sclerosis Research - Jul 20 2014]
Rebound post-natalizumab: is it such a problem? #MSBlog #MSResearch "The study below reports MS rebound post-natalizumab. They make a general statement that 'no treatment is unable to abolish disease activity reactivation after natalizumab discontinuation' ...
1 2 3

Press Releases

sort by: Date | Relevance
Nuvilex and Austrianova Announce Results of Cli... [Published GlobeNewswire: Acquisitions News - Jul 17 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.